Astellas Pharma Inc

Overview

Astellas Pharma Inc (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, nephrology, and metabolic diseases, immunodeficiency diseases, and transplantation. Its pipeline portfolio encompasses candidates for the treatment of urothelial cancer; gastric cancer; gastroesophageal junction cancer; anemia associated with chronic kidney disease (CKD) in dialysis and non-dialysis patients; menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and acute myeloid leukemia (AML), among others. It operates in the Americas, China, Japan, Australia, Europe, and Asia and Oceania through its network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.
Key Stats
Address
2-5-1, Nihombashihon-cho, CHUO-KU, Tokyo
Headquarters

Japan

Contact

81 3 32443000

No of Employees

15,455

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

4503 [TYO]

Revenue (2021)

$11,786 m

-4% (2021 vs 2020)
Net Income (2021)

$1,137 m

-38.3% (2021 vs 2020)
Net Profit Margin

10 %

-35.8% (2021 vs 2020)
Market Cap *

$32,581 m

EPS *

$0.6

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Astellas Pharma IncDaiichi Sankyo Co LtdEisai Co LtdKyowa Kirin Co Ltd
Key Information
Headquarters Japan Japan Japan Japan
Headquarter City CHUO-KU CHUO-KU BUNKYO-KU CHIYODA-KU
Headquarter State/Province Tokyo Tokyo Tokyo Tokyo
No. of Employees 15,455 16,033 11,237 5,423
Entity Type Public Public Public Public

Products & Services

Astellas is a pharmaceutical company that researches, develops, and markets pharmaceuticals for urological diseases, transplantation, and cancer. The company’s key products and brands include the following:

Products
  • Xtandi- Treatment of Prostate Cancer
  • Xospata- Acute Myeloid Leukemia
  • Padcev- Metastatic Urothelial Cancer
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Services
  • Contract Manufacturing:
  • API Chemical
  • Clinical Dose
  • Etiam Rutrum Elit
  • Etiam Rutrum Elit
  • Etiam Rutrum Elit
  • Etiam Rutrum Elit
Brands
  • Celecox
  • Lipitor
  • Micardis
  • Rutrum Elit
  • Rutrum Elit
  • Rutrum Elit
  • Rutrum Elit
  • Rutrum Elit
  • Rutrum Elit
  • Rutrum Elit
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Kenji Yasukawa Chief Executive Officer; Director; President Executive Board 2018 - Mr. Kenji Yasukawa been serving as the President and the Chief Executive Officer of the company since 2018, and a...
Yoshihiko Hatanaka Chairman Executive Board 2018 57 Mr. Yoshihiko Hatanaka been serving as the Chairman of the Board of the company since 2018, and as a Director...
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Contracts/Agreements In March, the company entered into two joint research agreement with Doshisha University, Wakayama Medical…
2021 Contracts/Agreements In May, the company signed a strategic alliance agreement with Kyoto University Innovation Capital to…
2021 Contracts/Agreements In January, the company along with Amgen, Pfizer, Bristol Myers Squibb, GSK, Janssen, Lilly, Sanofi,…
2021 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2021 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2021 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Astellas Pharma GmbH

Address

Georg-Brauchle-Ring 64-66, Munich
Germany

Telephone

49 89 45440100

Website

www.astellas.com/de/
Astellas Pharma Manufacturing Inc

Address

325 Staley Road, Grand Island
United States of America

Telephone

1 716 7752200

Astellas Pharma Europe Ltd

Address

Bourne Business Park, 300 Dashwood Lang Road, Addlestone
United Kingdom

Telephone

44 203 3798000

Website

www.astellas.com/
Ogeda SA

Address

47 Rue Adrienne Bolland, Gosselies
Belgium

Telephone

32 71 348500

Website

www.ogeda.com
Astellas Ireland Co Ltd

Address

Citywest Business Campus, Dublin
Ireland

Telephone

353 1 4671555

Website

www.astellas.ie
Astellas Pharma Korea Inc

Address

401, Gangnam-ro, Gangnam-gu, Seoul
South Korea

Telephone

82 2 34480504

Website

www.astellas.co.kr
Astellas Pharma India Pvt Ltd

Address

301, 3rd Floor, C and B Square, 127 Andheri Kurla Road, Chakala, Andheri East, Mumbai
India

Telephone

91 22 61557600

Website

www.astellas.com/in
Astellas Pharma (Thailand) Co Ltd

Address

19th Floor, Room No. 1908-1914, No. 1788 Singha Complex Building, New Petchaburi Road, Khwaeng Bangkapi, Khet Huai Kwang, Bangkok
Thailand

Telephone

66 2 09696005

Website

www.astellas.com/th/en

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
30 Jul 2021 Astellas Pharma Enters into Licensing Agreement with Minovia Therapeutics Licensing Agreement Astellas Pharma Inc Minovia Therapeutics Ltd
15 Jun 2021 Cheplapharm Arzneimittel to Acquire Five Product Rights from Astellas Pharma Asset Transaction CHEPLAPHARM Arzneimittel GmbH Astellas Pharma Inc
11 May 2021 Autobahn Therapeutics Acquires ASP3652 from Astellas Pharma Asset Transaction Autobahn Therapeutics Inc Astellas Pharma Inc
27 Apr 2021 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
22 Apr 2021 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
01 Apr 2021 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

113

Active Jobs

64

Posted

46

Closed

Job Trends

Latest Jobs

Job title Company Country
Data management (Data Science Department, Development Headquarters) Astellas Pharma Inc Japan
Customer success Astellas Pharma Inc Japan
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar